-+ 0.00%
-+ 0.00%
-+ 0.00%

Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies

Reuters·09/05/2025 12:35:54

Please log in to view news